Pipeline
ADEL-Y07
ADEL-Y07
ADTAC™
ADY-71001
Target Type
Androgen Receptor
Indication
Prostate cancer
Development stage
Hit-to-Lead
ADY-73001
Target Type
Tau aggregates
Indication
Alzheimer's Disease
Development stage
Hit-to-Lead
Related Figures and/or Summary
- ADY-71001 is a target protein decomposition compound targeting Androgen receptors and is being developed as a prostate cancer treatment agent.
- ADY-73001 is a target protein decomposition compound that targets tau and is being developed as an alzheimer’s treatment.
Development stage
- Hit-to-Lead generation & optimization
- Target to lead
ADTAC pipeline and development plan
current
Neuro generation
- Indication
- Alzheimer’s disease
- Target Protein
- ADY-73001
Tau
- Indication
- Amyolateral sclerosis
- Target Protein
- ADY-74001
TDP43
Amyloidosis
- Indication
- hATTR
amyloidosis>- Target Protein
- ADY-7201
Mutant-transthyretin
Cancer
- Indication
- Solid tumor
- Target Protein
- ADY-71001
AR
- Indication
- Solid tumor
- Target Protein
- ADY-76001
BRD4
- Indication
- Solid tumor
- Target Protein
- ADY-75001
KRAS
Muscular Dystrophy
- Indication
- Duchene muscular dystrophy
- Target Protein
- ADY-77001
ATE1
Infectious disease
- Indication
- Multi-drug resistance/Sepsis
- Target Protein
- ADY-78001
Bacteria/Virus
Metabolic diseases
- Indication
- Obesity
- Target Protein
- ADY-79001-1
Lipophagy
- Indication
- Diabetes
- Target Protein
- ADY-79001-2
Lipophasy